BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Prednisone: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Jiangsu HengRui Medicine Co., Ltd., Prevail Therapeutics, Incyte Corporation, Myrtelle Inc., Celgene. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04691804 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus PlacebMetastatic Castration-Resistant Prostate Cancer (mCRPC)active not recruiting496
2027-02 est.P1/P2Prevail TherapeuticsNCT04411654 Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Gaucher Disease, Type 2active not recruiting7

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-01 est.P3Incyte Corporation INCYNCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsDiffuse Large B-cell Lymphomaactive not recruiting899
2026-08-31 est.P1/P2Myrtelle Inc.NCT04833907 rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan DiseaseCanavan Diseaseenrolling by invitation24
2026-06-19P2CelgeneNCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaLymphoma, Follicularactive not recruiting95

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.